Table 2 The baseline characteristics of the included studies
Author | Source | Type | NC | DAPT (months) | FU (months) | Age (BP/DP) | Male (BP/DP) | Diabetes (BP/DP) (%) | Type B2/C (BP/DP) (%) | Lesion length (mean ± SD) | Reference diameter (mean ± SD) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BP | DP | BP | DP | BP | DP | |||||||||
Chevalier [19] | EuroInterv 2007 | BES | PES | 120 | 6 | 9 | 65/63 | 69/66 | 18/26 | 56.47/68.57 | 11.35 ± 4.51 | 11.03 ± 4.75 | 2.70 ± 0.44 | 2.60 ± 0.57 |
Byrne [20] | Heart 2009 | SES | SES | 404 | 12 | 24 | 66.5/65 | 79.3/78.2 | 27.4/28.7 | NA | 13.9 ± 7.2 | 14.6 ± 7.0 | 2.74 ± 0.59 | 2.80 ± 0.52 |
Chevalier [21] | Circ Cardiovasc Intervent 2009 | BES | PES | 243 | 6 | 9 | 62.7/63.2 | 74.5/68.9 | 16.3/27.8 | 49.67/44.44 | 10.56 | 10.84 | 2.72 | 2.73 |
Stefanini [22] | Lancet 2011 | BES | SES | 1,707 | 12 | 48 | 64.6/64.5 | 75.0/74.6 | 26.0/22.5 | NA | 15.2 ± 11.7 | 14.4 ± 10.6 | 2.60 ± 0.61 | 2.71 ± 0.52 |
Byrne [23] | JACC 2011 | SES | EESSES | 2,603 | 6 | 36 | 66.7/66.8 | 77.8/75.9 | 28.2/29.6 | 72.8/72.1 | 14.8 ± 8.6 | 15.0 ± 8.8 | 2.79 ± 0.47 | 2.75 ± 0.51 |
Maamoun [24] | The Egyptian Heart Journal 2012 | BES | SESPES | 145 | 6 | 24 | 56.7/54.2 | 87.1/85.5 | NA | NA | NA | NA | NA | NA |
Kadota [25] | CCI 2012 | BES | SES | 326 | 3 | 9 | 67.1/67.7 | 71.6/72.0 | 38.7/39.4 | 69.7/62.0 | 12.64 ± 5.52 | 12.82 ± 6.81 | 2.68 ± 0.57 | 2.68 ± 0.54 |
Xu [26] | EuroInterv 2012 | SES | SES | 300 | 12 | 24 | 56.6/56.7 | 66.7/72 | 22/20 | 47.0/41.7 | 17.74 ± 9.30 | 18.72 ± 9.98 | NA | NA |
Tan [27] | Chin J Clinicians 2012 | BES | EES | 50 | 12 | 24 | 62/63 | 70.0/73.3 | 20.0/23.3 | NA | NA | NA | NA | NA |
Ge [28] | JACC 2012 | SES | SES | 1,909 | 12 | 12 | 63.3/62.1 | 67.7/73.0 | 20.5/20.75 | NA | NA | NA | NA | NA |
Smits [29] | Lancet 2013 | BES | EES | 2,707 | 12 | 12 | 63/62.7 | 74.4/74.3 | 21.8/21.6 | 63.7/63.3 | 16.8 ± 9.8 | 17.7 ± 10.6 | 2.9 ± 0.5 | 2.9 ± 0.5 |
Zhang [30] | INT J CARDIOL 2013 | SES | SES | 662 | 12 | 24 | 65.9/67.5 | 68.5/69.2 | 27.73/32.26 | 66.34/69.51 | 24.77 ± 14.47 | 29.20 ± 16.6 | 3.13 ± 0.45 | 3.26 ± 2.40 |
Natsuaki [31] | JACC 2013 | BES | EES | 3,235 | 3 | 12 | 69.1/69.3 | 77/77 | 46/46 | NA | 19.5 ± 12.8 | 19.3 ± 13.1 | 2.62 ± 0.6 | 2.61 ± 0.57 |
Raungaard [32] | Lancet 2015 | BES | ZES | 2,999 | 12 | 12 | 65.8/65.7 | 76.2/75.8 | 17.6/18.0 | 63/70 | 15.0 | 16.0 | 3.0 | 3.2 |
Han [33] | JACC 2014 | SES | SES | 2,737 | 6 | 12 | 60.2/60.2 | 68/70 | 22.6/21.3 | 83.5/85.1 | 20.6 ± 12.3 | 21.2 ± 12.9 | 2.79 ± 0.47 | 2.79 ± 0.44 |
Pilgrim [34] | Lancet 2014 | SES | EES | 2,119 | 12 | 12 | 66.1/65.9 | 77.0/77.3 | 24.2/21.7 | NA | 25.91 ± 15.40 | 27.45 ± 16.77 | 3.05 ± 0.49 | 3.03 ± 0.49 |